MGRX

Mangoceuticals, Inc. is focused on developing men’s and women’s health and wellness products and services via a secure telemedicine platform. The Company connects consumers to licensed healthcare professionals through its Website at www.MangoRX.com, for the provision of care via telehealth on its customer portal. It has developed and is commercially marketing a brand of erectile dysfunction (ED) products under the brand name Mango, a brand of hair-loss products under the brand name Grow, a brand of hormone balance and therapy products under the name Mojo, and a brand of weight-loss products under the brand name Slim. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. Mango GROW includes four ingredients: Minoxidil (the active ingredient in Rogaine) and Finasteride (the active ingredient in Propecia), Vitamin D3 and Biotin, which are available as dietary supplements.

Wall Street analysts forecast MGRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGRX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Mangoceuticals Inc revenue for the last quarter amounts to 84.25K USD, decreased -36.83 % YoY.

Mangoceuticals Inc. EPS for the last quarter amounts to -0.69 USD, decreased -95.35 % YoY.

Mangoceuticals Inc (MGRX) has 0 emplpoyees as of December 15 2025.

Today MGRX has the market capitalization of 15.71M USD.